Scleroderma lung disease

European Respiratory Review

Volumn 22, Issue 127, 2013, Pages 6-19

  Solomon, Joshua J ^a   Olson, Amy L ^a   Fischer, Aryeh ^a   Bull, Todd ^b   Brown, Kevin K ^a   Raghu, Ganesh ^c  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; AMLODIPINE; AZATHIOPRINE; BERAPROST; BOSENTAN; COLLAGEN; CORTICOSTEROID; CREATINE KINASE; CREATININE; CYCLOPHOSPHAMIDE; DILTIAZEM; ENDOTHELIN RECEPTOR ANTAGONIST; GAMMA INTERFERON; ILOPROST; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; PREDNISONE; PROSTACYCLIN; SILDENAFIL; TADALAFIL; TREPROSTINIL;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; EMPHYSEMA; ETHNICITY; HEART CATHETERIZATION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG BIOPSY; LUNG FUNCTION TEST; LUNG INFECTION; LUNG LAVAGE; LUNG NODULE; LUNG TOXICITY; PATHOGENESIS; PREVALENCE; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RISK FACTOR; SCLERODERMA; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

HUMANS; HYPERTENSION, PULMONARY; LUNG; LUNG DISEASES, INTERSTITIAL; LUNG TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; RESPIRATORY SYSTEM AGENTS; RISK FACTORS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 84874703619     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00005512     Document Type: Article

References (179)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
2. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-944.
3. Morelli S, Barbieri C, Sgreccia A, et al. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 1997; 24: 81-85.
4. Highland KB, Garin MC, Brown KK. The spectrumof scleroderma lung disease. Semin Respir Crit Care Med 2007; 28: 418-429.
5. Toya SP, Tzelepis GE. The many faces of scleroderma sine scleroderma: a literature review focusing on cardiopulmonary complications. Rheumatol Int 2009; 29: 861-868.
6. Fischer A, Meehan RT, Feghali-Bostwick CA, et al. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest 2006; 130: 976-981.
7. Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, et al. Anti-th/to- positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 2006; 33: 1600-1605.
8. D'Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46: 428-440.
9. Weaver AL, Divertie MB, Titus JL. Pulmonary scleroderma. Dis Chest 1968; 54: 490-498.
10. Schurawitzki H, Stiglbauer R, Graninger W, et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 1990; 176: 755-759.
11. Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-1289.
12. Steen VD, Owens GR, Fino GJ, et al. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985; 28: 759-767.
13. McNearney TA, Reveille JD, Fischbach M, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007; 57: 318-326.
14. Greidinger EL, Flaherty KT, White B, et al. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998; 114: 801-807.
15. Briggs DC, Vaughan RW, Welsh KI, et al. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991; 338: 661-662.
16. Steele R, Hudson M, Lo E, et al. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 2012; 64: 519-524.
17. Lewandowska K, Ciurzynski M, Gorska E, et al. Antiendothelial cells antibodies in patients with systemic sclerosis in relation to pulmonary hypertension and lung fibrosis. Ad Exp Med Biol 2013; 756: 147-153.
18. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35: 35-42.
19. Launay D, Remy-Jardin M, Michon-Pasturel U, et al. High resolution computed tomography in fibrosing alveolitis asso- ciated with systemic sclerosis. J Rheumatol 2006; 33: 1789-1801.
20. Ostojic P, Damjanov N. Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis. Clin Rheumatol 2006; 25: 453-457.
21. Morgan C, Knight C, Lunt M, et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003; 62: 146-150.
22. Tamby MC, Chanseaud Y, Guillevin L, et al. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003; 2: 152-157.
23. Bolster MB, Ludwicka A, Sutherland SE, et al. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997; 40: 743-751.
24. Weiner ES, Earnshaw WC, Senecal JL, et al. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum 1988; 31: 378-385.
25. Terrier B, Tamby MC, Camoin L, et al. Antifibroblast antibodies from systemic sclerosis patients bind to a-enolase and are associated with interstitial lung disease. Ann Rheum Dis 2010; 69: 428-433.
26. Chizzolini C, Raschi E, Rezzonico R, et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002; 46: 1602-1613.
27. Devenyi K, Czirjak L. High resolution computed tomography for the evaluation of lung involvement in 101 patients with scleroderma. Clin Rheumatol 1995; 14: 633-640.
28. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-1254.
29. Shah RM, Jimenez S, Wechsler R. Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis. J Thorac Imaging 2007; 22: 120-124.
30. Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneu- monia. Radiology 2004; 232: 560-567.
31. Goldin JG, Lynch DA, Strollo DC, et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008; 134: 358-367.
32. Wells AU, Hansell DM, Corrin B, et al. High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 1992; 47: 738-742.
33. Remy-Jardin M, Remy J, Wallaert B, et al. Pulmonary involve- ment in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology 1993; 188: 499-506.
34. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-2444.
35. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-1586.
36. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997; 40: 1229-1236.
37. Meyer KC, Raghu G. Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? Eur Respir J 2011; 38: 761-769.
38. De Santis M, Bosello S, La Torre G, et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res 2005; 6: 96.
39. Silver RM, Miller KS, Kinsella MB, et al. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88: 470-476.
40. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-954.
41. Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis- associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007; 56: 2005-2012.
42. Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177: 91-98.
43. Baughman RP, Raghu G. Bronchoalveolar cellular analysis in scleroderma lung disease: does Sutton's law hold? Am J Respir Crit Care Med 2008; 177: 2-3.
44. Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/ fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994; 18: 136-147.
45. Fujita J, Yoshinouchi T, Ohtsuki Y, et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001; 60: 281-283.
46. Song JW, Do KH, Kim MY, et al. Pathologic and radiologic differences between idiopathic and collagen vascular disease- related usual interstitial pneumonia. Chest 2009; 136: 23-30.
47. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613-1619.
48. Teixeira L, Mouthon L, Mahr A, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008; 67: 110-116.
49. Steen VD, Owens GR, Redmond C, et al. The effect of D- penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 1985; 28: 882-888.
50. Steen VD, Blair S, Medsger TA Jr. The toxicity of D-penicillamine in systemic sclerosis. Ann Intern Med 1986; 104: 699-705.
51. Polisson RP, Gilkeson GS, Pyun EH, et al. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol 1996; 23: 654-658.
52. Tzouvelekis A, Galanopoulos N, Bouros E, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med 2012; 2012: 143637.
53. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated inter- stitial lung disease. Chest 2008; 133: 455-460.
54. Nihtyanova SI, Brough GM, Black CM, et al. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis - a retrospective analysis. Rheumatology (Oxford) 2007; 46: 442-445.
55. Swigris JJ, Olson AL, Fischer A, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130: 30-36.
56. Zamora AC, Wolters PJ, Collard HR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008; 102: 150-155.
57. Mendoza FA, Nagle SJ, Lee JB, et al. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 2012; 39: 1241-1247.
58. Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 2001; 40: 84-88.
59. Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 2006; 45: 1005-1008.
60. Nihtyanova SI, Brough GM, Black CM, et al. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology (Oxford) 2007; 46: 442-445.
61. Akesson A, Scheja A, Lundin A, et al. Improved pulmonary function in systemic sclerosis after treatment with cyclopho- sphamide. Arthritis Rheum 1994; 37: 729-735.
62. Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20: 838-844.
63. Steen VD, Lanz JK Jr, Conte C, et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994; 37: 1290-1296.
64. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666.
65. Wells AU, Latsi P, McCune WJ. Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepre- sented in this trial? Am J Respir Crit Care Med 2007; 176: 952-953.
66. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026-1034.
67. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-3970.
68. Nannini C, West CP, Erwin PJ, et al. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008; 10: R124.
69. Saggar R, Khanna D, Mayes MD, et al. Open labeled study of imatinib mesylate (Gleevec) in the treatment of systemic sclerosis- associated active interstitial lung disease (SSc-ILD): preliminary results. Am J Respir Crit Care Med 2010; 181: A3991.
70. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of- principle study. Rheumatology (Oxford) 2010; 49: 271-280.
71. Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012; 30: Suppl. 71, S17-S22.
72. Becker MO, Bruckner C, Scherer HU, et al. The monoclonal anti- CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study. Ann Rheum Dis 2011; 70: 1340-1341.
73. Launay D, Marjanovic Z, de Bazelaire C, et al. Autologous hematopoietic stem cell transplant in systemic sclerosis: quanti- tative high resolution computed tomography of the chest scoring. J Rheumatol 2009; 36: 1460-1463.
74. Tsukamoto H, Nagafuji K, Horiuchi T, et al. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis 2006; 65: 508-514.
75. Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498-506.
76. Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994; 149: 1583-1590.
77. Hoeper MM. Pulmonary hypertension in collagen vascular disease. Eur Respir J 2002; 19: 571-576.
78. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54.
79. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S55-S66.
80. Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996; 110: 1515-1519.
81. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001; 40: 453-459.
82. Avouac J, Airo P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37: 2290-2298.
83. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis and rheuma- tism 2005; 52: 3792-3800.
84. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-1093.
85. Phung S, Strange G, Chung LP, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 2009; 39: 682-691.
86. Hachulla E, Launay D, Mouthon L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest 2009; 136: 1211-1219.
87. Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515-524.
88. Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983; 75: 65-74.
89. Cox SR, Walker JG, Coleman M, et al. Isolated pulmonary hypertension in scleroderma. Intern Med J 2005; 35: 28-33.
90. Schachna L, Wigley FM, Chang B, et al. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003; 124: 2098-2104.
91. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-522.
92. Yamane K, Ihn H, Asano Y, et al. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatol 2000; 39: 1269-1271.
93. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hyper- tension. Arthritis Rheum 2006; 54: 3043-3050.
94. Ong YY, Nikoloutsopoulos T, Bond CP, et al. Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension. Asian Pac J Allergy Immunol 1998; 16: 81-86.
95. Okano Y, Steen VD, Medsger TA Jr. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992; 35: 95-100.
96. Grigolo B, Mazzetti I, Meliconi R, et al. Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35. Clin Exp Immunol 2000; 121: 539-543.
97. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754-763.
98. Clements PJ, Tan M, McLaughlin VV, et al. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis 2012; 71: 249-252.
99. Morse J, Barst R, Horn E, et al. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol 2002; 29: 2379-2381.
100. Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011; 63: 783-794.
101. Risbano MG, Meadows CA, Coldren CD, et al. Altered immune phenotype in peripheral blood cells of patients with scleroderma- associated pulmonary hypertension. Clin Transl Sci 2010; 3: 210-218.
102. Dib H, Tamby MC, Bussone G, et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J 2012; 39: 1405-1414.
103. Pignone A, Scaletti C, Matucci-Cerinic M, et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 1998; 16: 527-532.
104. Tamby MC, Chanseaud Y, Humbert M, et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005; 60: 765-772.
105. Tamby MC, Humbert M, Guilpain P, et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J 2006; 28: 799-807.
106. Coral-Alvarado P, Quintana G, Garces MF, et al. Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis. Rheumatol Int 2009; 29: 1017-1024.
107. Nickel N, Kempf T, Tapken H, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 534-541.
108. Meadows CA, Risbano MG, Zhang L, etal. Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. Chest 2011; 139: 994-1002.
109. Denton CP, Cailes JB, Phillips GD, et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997; 36: 239-243.
110. Sweiss NJ, Hushaw L, Thenappan T, et al. Diagnosis and management of pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep 2010; 12: 8-18.
111. Pandey AK, Wilcox P, Mayo JR, et al. Predictors of pulmonary hypertension on high-resolution computed tomography of the chest in systemic sclerosis: a retrospective analysis. Can Assoc Radiol J 2010; 61: 291-296.
112. Fischer A, Misumi S, Curran-Everett D, et al. Pericardial abnormalities predict the presence of echocardiographically defined pulmonary arterial hypertension in systemic sclerosis- related interstitial lung disease. Chest 2007; 131: 988-992.
113. Steen VD, Graham G, Conte C, et al. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35: 765-770.
114. Young RH, Mark GJ. Pulmonary vascular changes in sclero- derma. Am J Med 1978; 64: 998-1004.
115. Norton WL, Nardo JM. Vascular disease in progressive systemic sclerosis (scleroderma). Ann Intern Med 1970; 73: 317-324.
116. al-Sabbagh MR, Steen VD, Zee BC, et al. Pulmonary arterial histology and morphometry in systemic sclerosis: a case-control autopsy study. J Rheumatol 1989; 16: 1038-1042.
117. Cool CD, Kennedy D, Voelkel NF, et al. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997; 28: 434-442.
118. Overbeek MJ, Vonk MC, Boonstra A, et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinc- tive vasculopathy. Eur Respir J 2009; 34: 371-379.
119. Toshner M, Tajsic T, Morrell NW. Pulmonary hypertension: advances in pathogenesis and treatment. Br Med Bull 2010; 94: 21-32.
120. Baliga RS, MacAllister RJ, Hobbs AJ. New perspectives for the treatment of pulmonary hypertension. Br J Pharmacol 2011; 163: 125-140.
121. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425-434.
122. McLaughlin V, Humbert M, Coghlan G, et al. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 2009; 48: Suppl. 3, iii25-iii31.
123. Safdar Z. Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs. Respir Med 2011; 105: 818-827.
124. Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004; 126: 420-427.
125. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915-1922.
126. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care 2006; 174: 1257-1263.
127. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
128. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hyperten- sion. N Engl J Med 1993; 328: 1732-1739.
129. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
130. Girgis RE, Mathai SC, Krishnan JA, et al. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hyperten- sion and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 2005; 24: 1626-1631.
131. Denton CP, Pope JE, Peter HH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 2008; 67: 1222-1228.
132. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-3019.
133. Rubin LJ. Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension (PAH): results from the SERAPHIN trial paper. Chest 2012; 142: 1026A.
134. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
135. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
136. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-350.
137. Chang B, Schachna L, White B, et al. Natural history of mild- moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006; 33: 269-274.
138. Dimitroulas T, Giannakoulas G, Papadopoulou K, et al. Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neuro- hormonal activation and endothelial dysfunction. J Rheumatol 2010; 37: 993-999.
139. Meune C, Avouac J, Wahbi K, et al. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 2008; 58: 1803-1809.
140. Hachulla AL, Launay D, Gaxotte V, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009; 68: 1878-1884.
141. Vonk Noordegraaf A, Naeije R. Right ventricular function in scleroderma-related pulmonary hypertension. Rheumatology 2008; 47: Suppl. 5, v42-v43.
142. Johnson SR, Patsios D, Hwang DM, et al. Pulmonary veno- occlusive disease and scleroderma associated pulmonary hyper- tension. J Rheumatol 2006; 33: 2347-2350.
143. Chang B, Wigley FM, White B, et al. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003; 30: 2398-2405.
144. Launay D, Mouthon L, Hachulla E, et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol 2007; 34: 1005-1011.
145. Trad S, Amoura Z, Beigelman C, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006; 54: 184-191.
146. Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60: 569-577.
147. Vachiery JL, Coghlan G. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2009; 18: 162-169.
148. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-2278.
149. Denton CP, Hachulla E. Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. Eur Respir Rev 2011; 20: 270-276.
150. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-628.
151. Bae S, Saggar R, Bolster MB, et al. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Dis 2012; 71: 1335-1342.
152. Kovacs G, Maier R, Aberer E, et al. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum 2012; 64: 1257-1262.
153. Shitrit D, Amital A, Peled N, et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant 2009; 23: 178-183.
154. Schachna L, Medsger TA Jr, Dauber JH, et al. Lung transplanta- tion in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum 2006; 54: 3954-3961.
155. Bjerke RD, Tashkin DP, Clements PJ, et al. Small airways in progressive systemic sclerosis (PSS). Am J Med 1979; 66: 201-209.
156. Kostopoulos C, Rassidakis A, Sfikakis PP, et al. Small airways dysfunction in systemic sclerosis. A controlled study. Chest 1992; 102: 875-881.
157. Ntoumazios SK, Voulgari PV, Potsis K, et al. Esophageal involvement in scleroderma: gastroesophageal reflux, the com- mon problem. Semin Arthritis Rheum 2006; 36: 173-181.
158. Thompson AE, Pope JE. A study of the frequency of pericardial and pleural effusions in scleroderma. Br J Rheumatol 1998; 37: 1320-1323.
159. Taormina VJ, Miller WT, Gefter WB, et al. Progressive systemic sclerosis subgroups: variable pulmonary features. AJR Am J Roentgenol 1981; 137: 277-285.
160. Yoon J, Finger DR, Pina JS. Spontaneous pneumothorax in scleroderma. J Clin Rheumatol 2004; 10: 207-209.
161. Johnson DA, Drane WE, Curran J, et al. Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch Iintern Med 1989; 149: 589-593.
162. Maddern GJ, Horowitz M, Jamieson GG, et al. Abnormalities of esophageal and gastric emptying in progressive systemic sclerosis. Gastroenterology 1984; 87: 922-926.
163. Christmann RB, Wells AU, Capelozzi VL, et al. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum 2010; 40: 241-249.
164. Marie I, Dominique S, Levesque H, et al. Esophageal involve- ment and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001; 45: 346-354.
165. Savarino E, Bazzica M, Zentilin P, et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009; 179: 408-413.
166. Gilson M, Zerkak D, Wipff J, et al. Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J 2010; 35: 112-117.
167. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-1815.
168. Iikuni N, Kitahama M, Ohta S, et al. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol 2006; 16: 282-288.
169. Kremer JM, Alarcon GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-asso- ciated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997; 40: 1829-1837.
170. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumo- nitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000; 15: 373-381.
171. Malik SW, Myers JL, DeRemee RA, et al. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996; 154: 1851-1856.
172. Bedrossian CW, Sussman J, Conklin RH, et al. Azathioprine- associated interstitial pneumonitis. Am J Clin Pathol 1984; 82: 148-154.
173. Talbott JH, Barrocas M. Carcinoma of the lung in progressive systemic sclerosis: a tabular review of the literature and a detailed report of the roentgenographic changes in two cases. Seminars in arthritis and rheumatism 1980; 9: 191-217.
174. Wooten M. Systemic sclerosis and malignancy: a review of the literature. South Med J 2008; 101: 59-62.
175. Calore EE, Cavaliere MJ, Perez NM, et al. Skeletal muscle pathology in systemic sclerosis. J Rheumatol 1995; 22: 2246-2249.
176. Ringel RA, Brick JE, Brick JF, et al. Muscle involvement in the scleroderma syndromes. Arch Intern Med 1990; 150: 2550-2552.
177. Chausow AM, Kane T, Levinson D, et al. Reversible hypercapnic respiratory insufficiency in scleroderma caused by respiratory muscle weakness. Am Rev Respir Dis 1984; 130: 142-144.
178. Pugazhenthi M, Cooper D, Ratnakant BS, et al. Hypercapnic respiratory failure in systemic sclerosis. J Clin Rheumatol 2003; 9: 43-46.
179. Aguayo SM, Richardson CL, Roman J. Severe extrapulmonary thoracic restriction caused by morphea, a form of localized scleroderma. Chest 1993; 104: 1304-1305.